Breakthrough T1D Awards Grant for Expanded SAB-142 Study in Type 1 Diabetes
SABS has more than doubled off its 52-week low of $1.715.
Summary
Breakthrough T1D has awarded a grant to support the PRISE-hATG clinical study of SAB-142 for Stage 3 Type 1 Diabetes, with SAB Biotherapeutics co-funding. This new investigator-led study expands the clinical evaluation of SAB-142 into patients beyond 100 days from diagnosis, complementing the ongoing Phase 2b SAFEGUARD trial. The grant from a leading T1D research organization provides external validation and financial support for SAB-142, which has seen a series of positive developments including strong Phase 1 data and regulatory updates. This move could significantly broaden the drug's potential market.
At the time of this announcement, SABS was trading at $4.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $299.7M. The 52-week trading range was $1.72 to $6.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.